Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of this dose-escalating trial is to assess the
safety, tolerability, pharmacokinetics (the rate at which the body eliminates the trial drug)
and pharmacodynamics (the effect of the investigated drug on the body) of single and repeated
doses of NNC141-0100 in subjects with Rheumatoid Arthritis.